Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography

Stefan Kralev*, Kathrin Schneider, Siegfried Lang, Tim Süsselbeck, Martin Borggrefe

Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany

Abstract

**Background:** In standard reference sources, the incidence of coronary artery disease (CAD) in patients with atrial fibrillation (AF) ranged between 24 and 46.5%. Since then, the incidence of cardiovascular risk factors (CRF) has increased and modern treatment strategies (“pill in the pocket”) are only applicable to patients without structural heart disease. The aim of this study was to investigate the incidence and severity of CAD in patients with AF.

**Methods:** From January 2005 until December 2009, we included 261 consecutive patients admitted to hospital with paroxysmal, persistent or permanent AF in this prospective study. All patients underwent coronary angiography and the Framingham risk score (FRS) was calculated. Patients with previously diagnosed or previously excluded CAD were excluded.

**Results:** The overall incidence of CAD in patients presenting with AF was 34%; in patients >70 years, the incidence of CAD was 41%. The incidence of patients undergoing a percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) was 21%. Patients with CAD were older (73±8 years vs 68±10 years, p = 0.001), had significantly more frequent hypercholesterolemia (60% vs 30%, p<0.001), were more frequent smokers (26% vs 13%, p = 0.017) and suffered from angina more often (37% vs 2%, p<0.001). There was a significant linear trend among the FRS categories in percentage and the prevalence of CAD and PCI/CABG (p<0.0001).

**Conclusions:** The overall incidence of CAD in patients presenting with AF was relatively high at 34%; the incidence of PCI/CABG was 21%. Based upon increasing CRF in the western world, we recommend a careful investigation respecting the FRS to either definitely exclude or establish an early diagnosis of CAD – which could contribute to an early and safe therapeutic strategy considering type Ic antiarrhythmics and oral anticoagulation.

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 2.3 million individuals in the USA and 4.5 million people in the EU [1]. AF is associated with multiple symptoms, significant mortality and morbidity and decreased quality of life [2,3].

Importantly, after acute myocardial infarction, development of AF is associated with a worse prognosis [4]. Common cardiovascular risk factors also give support to associate coronary artery disease (CAD) and AF. Previous studies have found that hypertension, diabetes and obesity are conditions predisposing to AF [5], although in the case of diabetes conflicting data have been reported [6]. The Framingham study suggested that angina predisposed to AF and that the association of AF with CAD was stronger in men [7]. Despite the high prevalence of CAD in patients with AF of 18–46.5% [8–12], the prevalence of AF among patients with proven CAD is extremely low, at 0.2–5% [13–16]. By contrast, a survey of historic literature by Zipes indicates that AF commonly occurs in patients with CAD [17].

Over recent years, the incidence of cardiovascular risk factors of the western world have dramatically increased and this trend is projected to continue. Newer studies report different incidences of CAD in patients with AF but also focus on different patient groups [12,18], so data is lacking on the overall incidence of CAD in AF patients in the modern era of cardiology. Further, the possibility of specific antiarrhythmic therapy has increased the interest in investigating patients with AF for CAD [19]. According to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines, there is a class I recommendation for flecainide and propafenone for pharmacological cardioversion and a class IIa recommendation for flecainide and propafenone for selected patients (“pill-in-the-pocket”) without structural heart disease [20].
The aim of the present study was to investigate invasively the incidence and severity of CAD in patients with AF, presenting without previously diagnosed or previously excluded CAD.

Methods

The study complies with the Declaration of Helsinki and all patients gave written informed consent. This study was approved by the Medical Ethic Commission II, Faculty of Medicine Mannheim, University of Heidelberg. The study was also performed in accordance with federal laws and regulations, international accreditation standards and institutional policies.

Patient selection

From January 2005 until December 2009 we included 261 consecutive patients admitted to hospital with paroxysmal, persistent or permanent AF in this prospective study. Independent of the rhythm on admission, patients with previously known AF as well as patients with diagnosed AF on admission were included. Patients with previously diagnosed or previously excluded CAD, acute coronary syndromes and dilated or hypertrophic cardiomyopathy were excluded.

All patients underwent coronary angiography and the Framingham risk score (FRS) was calculated. Type of AF (paroxysmal, persistent or permanent), baseline clinical data, cardiac risk factors, left ventricular (LV) systolic function, existence of angina pectoris, existence of hyperthyreosis, above-average alcohol consumption and medication at discharge were (among others) recorded. In patients diagnosed with CAD, the number of diseased vessels and the affected coronary artery [left anterior descending (LAD), left circumflex artery (LCX) and right coronary artery (RCA)] were assessed. Diagnosis of CAD and indication for percutaneous coronary intervention (PCI) was performed according to the current AHA/ACC guidelines [21]. In patients

Figure 1. Significant linear trend among the FRS categories in % and the prevalence of CAD and PCI/CABG (p<0.0001). CABG = Coronary Artery Bypass Graft, CAD = Coronary Artery Disease, FRS = Framingham Risk Score, PCI = Percutaneous Coronary Intervention. doi:10.1371/journal.pone.0024964.g001

The aim of the present study was to investigate invasively the incidence and severity of CAD in patients with AF, presenting without previously diagnosed or previously excluded CAD.

Figure 2. Incidence and severity of coronary artery disease in patients presenting with atrial fibrillation according to age. CAD = Coronary Artery Disease, PCI = Percutaneous Coronary Intervention. doi:10.1371/journal.pone.0024964.g002

Table 1. Comparison of patients without CAD and patients with CAD.

| Patient characteristic | Without CAD | With CAD | P-Value |
|------------------------|------------|----------|--------|
| Age ± SD (Years)       | 68±10      | 73±8     | 0.001  |
| Male sex               | 102 [60%]  | 65 [72%] | 0.057  |
| Type of AF             |            |          |        |
| Paroxysmal             | 77 [45%]   | 47 [52%] | 0.30   |
| Persistent             | 47 [27%]   | 16 [18%] | 0.095  |
| Permanent              | 47 [27%]   | 27 [30%] | 0.67   |
| Risk factors           |            |          |        |
| Smoking                | 23 [13%]   | 23 [26%] | 0.017  |
| Hypercholesterolemia   | 52 [30%]   | 54 [60%] | <0.001 |
| Hypertension           | 113 [66%]  | 65 [72%] | 0.33   |
| Obesity                | 38 [22%]   | 20 [22%] | 1.0    |
| Familiar history of CAD| 16 [9%]    | 9 [10%]  | 0.83   |
| Diabetes mellitus      | 25 [15%]   | 21 [23%] | 0.11   |
| Left ventricular systolic function* | | |
| EF=55%                 | 119 [70%]  | 52 [58%] | 0.075  |
| EF 45–54%              | 34 [20%]   | 22 [24%] | 0.43   |
| EF 30–44%              | 12 [7%]    | 11 [12%] | 0.17   |
| EF <30%                | 6 [4%]     | 5 [6%]   | 0.52   |
| Other data             |            |          |        |
| Angina pectoris        | 3 [2%]     | 33 [37%] | <0.001 |
| Above-average alcohol consumption | 5 [3%] | 2 [2%] | 1.0 |
| Hyperthyreosis         | 14 [8%]    | 14 [16%] | 0.091  |
| Medication at discharge|            |          |        |
| Aspirin                | 24 [14%]   | 47 [52%] | <0.001 |
| Clopidogrel            | 3 [2%]     | 39 [43%] | <0.001 |
| Phenprocoumon          | 119 [70%]  | 32 [36%] | <0.001 |
| Beta-blockers          | 118 [69%]  | 62 [69%] | 1.0    |
| Calcium channel antagonists | 26 [15%] | 17 [19%] | 0.48   |
| Digitalis glycosides   | 71 [42%]   | 44 [49%] | 0.29   |
| Amiodarone             | 7 [4%]     | 2 [2%]   | 0.72   |
| Flecainide             | 23 [13%]   | 5 [6%]   | 0.059  |
| Propafenone            | 16 [9%]    | 1 [1%]   | 0.008  |

AF = Atrial Fibrillation; CAD = Coronary Artery Disease; EF = Ejection Fraction; SD = Standard Deviation; *Significant “within-group” trend towards EF≥55%.

doi:10.1371/journal.pone.0024964.t001
undergoing PCI the target vessel was recorded. Additionally, patients undergoing coronary artery bypass graft (CABG) were noted.

**Statistical analysis**

For normally distributed data the unpaired Student’s t test was applied. The nonparametric Mann-Whitney U test was used when the data deviated from a Gaussian distribution as tested by the Kolmogorov-Smirnov test. Comparisons of categorial variables were carried out by χ² and Fisher’s exact tests. Data are presented as mean ± standard deviation (SD) or number and percentage for categorial variables. Values of p<0.05 (two-tailed) were considered statistically significant. The calculations were performed using SPSS-Software (SPSS-Software GmbH, München, Germany) and InStat (GraphPad Software, San Diego, USA).

**Results**

Overall, 261 patients with AF and unknown history of CAD were analysed. In 171 patients (65.5%) CAD was excluded. A stable CAD was diagnosed in 34 patients (13%) and PCI or CABG was performed in 56 patients (21%). No patient died, developed a stroke or a myocardial infarction. Nine patients underwent inhospital CABG. Among the patients with newly detected CAD, the percentage of patients undergoing PCI/CABG was 62.2%. Patients with CAD were older (73 ± 8 years vs 68 ± 10 years, p = 0.001), had significantly more frequent hypercholesterolemia (60% vs 30%, p<0.001), were more frequent smokers (26% vs 13%, p = 0.017) and suffered from angina more often (37% vs 2%, p<0.001). There was a significant linear trend among the FRS categories in % and the prevalence of CAD and PCI/CABG (p<0.0001) with more cases of PCI and CAD at elevated FRS levels. The association between the FRS and % of CAD in AF is presented in Figure 1. 61 patients (23%) in this study were 70 years old, and of these 25 (41%) presented with a CAD (Figure 2 shows the age-dependent distribution). The incidence of male gender was higher among patients with detected CAD, but did not reach statistical significance (72% vs 60%, p = 0.057). Therapy with a class Ic antiarrhythmic drug was initiated in 39 of 171 patients (23%). The comparison of patients with and without CAD is shown in Table 1; the overall incidence of CAD (in comparison to previous studies) is depicted in Figure 3.

Comparing patients with stable CAD and patients undergoing PCI/CABG (Table 2), patients with stable CAD presented more often with one-vessel disease (79% vs 34%, p<0.0001) and significantly less frequently with two- and three-vessel disease. In patients who underwent PCI, CAD was more frequently detected in the RCA (62% vs 26%, p = 0.001). Regarding age, gender and single cardiac risk factors, no differences were found between patients with stable CAD and patients undergoing PCI/CABG.

Patients without CAD and patients with stable CAD were pooled in one group and were compared with patients who underwent PCI/CABG (Table 3). Patients with PCI were older (74 ± 8 years vs 69 ± 10 years, p<0.001), were more frequently male (77% vs 60%, p = 0.028), had hypercholesterolemia more often (66% vs 34%, p<0.001) and had a significantly increased incidence of diabetes mellitus (29% vs 15%, p = 0.028). Patients with PCI also suffered from angina more often (41% vs 6%, p<0.001). The prevalence and management of CAD (drug-treated stable CAD vs. PCI/CABG) according to subtype of atrial fibrillation did not differ significantly (p = 0.79, χ² test) and is depicted in Figure 4. No significant differences were found when the different patient groups (without CAD, stable CAD, PCI) were compared for LV systolic function, but in all groups there was a significant “within-group” trend towards ejection fraction (EF) ≥55% (Tables 1, 2, and 3). Unsuccessful but also successful electrical cardioversion were more frequently performed in patients without CAD than in patients with stable CAD or with PCI/CABG (p<0.01, Figure 5).

**Discussion**

This single centre study reports on patients with AF undergoing first time coronary angiography, presenting data relating to the incidence and severity of CAD.

![Figure 3. Overview of reported incidences of coronary artery disease in patients presenting with atrial fibrillation.](https://www.plosone.org/doi/10.1371/journal.pone.0024964.g003)
AF and cardiovascular risk factors

The Framingham Heart Study [7] concluded that hypertension and diabetes are significantly associated with risk for AF. In addition, two other studies reported that hypertension, diabetes and obesity were conditions predisposing to AF [5]. Nevertheless, in the case of diabetes, data are contrasting. Whereas Movahed et al. [22] reported that diabetes is a strong independent risk factor for AF, Wilhelmsen et al. found no correlation between diabetes mellitus and AF [6]. In our study, only the comparison of patients without CAD or stable CAD versus patients undergoing PCI yielded a significantly higher incidence of diabetes in the PCI group (Table 3). Regarding other cardiovascular risk factors, patients with CAD (compared to patients without CAD) had significantly more frequent hyperlipidaemia, were more frequent smokers and were older. Importantly, the CHADS2 score (Congestive heart failure, Hypertension, Age $>$75, Diabetes, prior Stroke -doubled [23,24] or the refined CHA2DS2-VASc score (difference to CHADS2: AGE $>$75 years 2 points, AGE 65–74 years 1 point, Vascular disease [prior MI, peripheral artery disease or aortic plaque], Sex category) should be applied to enable a stratification of stroke risk [25]. In conclusion, at least a stress test is reasonable in AF patients with cardiovascular risk factors and, citing the guidelines, the presence of AF alone, without other stigmata of CAD, should prompt the cardiologist to search for causes of AF other than CAD ([20] page 11).

AF and LV function

Since patients with severe CAD are very likely to have impaired LV systolic function, heart failure seems more likely to be a cause of AF. Most of the patients included in this study had an EF$\geq$55%. There was a significant “within-group” trend [patient groups: without CAD, stable CAD, PCI] towards EF$\geq$55% and no significant difference was found comparing the different patient groups with each other regarding the incidence of EF<$50\%$, EF 50–44% or EF 45–54% (Tables 1, 2 and 3). In any event, in patients presenting with persistent signs of impaired LV dysfunction, coronary angiography and careful consideration about the underlying heart disease is recommended ([20] page 11). Ischemic cardiomyopathy, heart failure and neurohumoral activation are hypothesized to play an important mediating role in the development of new AF [3,13] and previous studies have demonstrated the occurrence of AF in congestive heart failure and in myocardial infarction [26]. We agree with Movahed et al. [22] that it is possible that coronary microvascular disease with ischemia (inducing metabolic stress) could be involved in the development of AF.

AF and CAD

In this study, the overall incidence of patients with CAD was 34%. Lip and Beevers [10] described an incidence of 46% and stated that CAD is one of the commonest causes of AF in the western world. Watson et al. investigated 121 outpatients with pacemakers capable of arrhythmia detection and found an incidence of CAD of 40% in the patient group with >50% time in AF [27]. On the other hand, Van Gelder et al. (investigating only patients with permanent AF) detected an incidence of CAD of 18% [18]. Crijns et al. [8] found an incidence of 24% and another study focusing on middle-aged (50±9 years) asymptomatic subjects with AF, reported an incidence of 22% [19]. All those studies focus on different patient groups, whereas in this study, symptomatic patients with angina were also included, as well as all types of AF. We found an overall incidence of CAD of 34%, which is in accordance with the incidence of 38% reported by the AFFIRM study [9] and the incidence of 30% reported by the ATHENA trial investigating dronedarone [12] - although this trial included only patients with paroxysmal or persistent AF. The incidence of CAD in patients with AF (36.3%) described by Krahn et al. [11] is also in accordance with our data. Interestingly, Krahn et al. found the strongest relative risk for AF at the onset of ischemic heart disease, diminishing over time [11]. For a better general survey, reported incidences are depicted in Figure 1.

The Framingham study reported that CAD was noted in 25% of the men who later had AF, but prevalence in the controls was 15%, so data did not reach statistical significance [3]. Importantly, a few months later additional Framingham data showed that the combination of AF and CAD adversely affected the prognosis regarding total mortality and that men with CAD had a statistically significant doubled risk of developing chronic AF [7].

| Table 2. Comparison of patients with stable CAD and patients undergoing PCI/CABG. |
|-------------------------------|-----------------|-----------------|----------------|
| Patient characteristics        | Stable CAD (n = 34) | PCI/CABG (n = 56) | P-Value       |
| Age ± SD (Years)              | 72±8            | 74±8            | 0.24          |
| Male sex                      | 22 [65%]        | 43 [77%]        | 0.23          |
| Risk factors                  |                 |                 |               |
| Smoking                       | 9 [26%]         | 14 [25%]        | 1.0           |
| Hypercholesterolemia          | 17 [50%]        | 37 [66%]        | 0.18          |
| Hypertension                  | 22 [65%]        | 43 [77%]        | 0.23          |
| Obesity                       | 9 [26%]         | 11 [20%]        | 0.6           |
| Familiar history of CAD       | 4 [12%]         | 5 [9%]          | 0.73          |
| Diabetes mellitus             | 5 [15%]         | 16 [29%]        | 0.15          |
| Angina pectoris               | 10 [29%]        | 23 [41%]        | 0.37          |
| Left ventricular systolic function* |              |                 |               |
| EF$\geq$55%                   | 19 [56%]        | 33 [59%]        | 0.83          |
| EF 45–54%                     | 8 [24%]         | 17 [30%]        | 0.63          |
| EF 30–44%                     | 6 [18%]         | 2 [4%]          | 0.058         |
| EF$<30\%$                     | 1 [3%]          | 4 [7%]          | 0.65          |
| Number of vessel disease      |                 |                 |               |
| 1-vessel disease              | 27 [79%]        | 19 [34%]        | $<0.0001$     |
| 2-vessel disease              | 4 [12%]         | 20 [36%]        | 0.015         |
| 3-vessel disease              | 3 [9%]          | 17 [30%]        | 0.019         |
| Localisation of CAD           |                 |                 |               |
| LAD                           | 23 [68%]        | 45 [80%]        | 0.21          |
| LCX                           | 12 [35%]        | 30 [54%]        | 0.13          |
| RCA                           | 9 [26%]         | 35 [62%]        | 0.001         |
| Target vessel                 |                 |                 |               |
| LAD                           | 27 [48%]        |                 |               |
| LCX                           | 8 [14%]         |                 |               |
| RCA                           | 12 [21%]        |                 |               |
| CABG                          | 9 [16%]         |                 |               |

AF = Atrial Fibrillation; CAD = Coronary Artery Disease; CABG = Coronary Artery Bypass Graft; EF = Ejection Fraction; LAD = Left Anterior Descending Artery; LCX = Left Circumflex Artery; PCI = Percutaneous Coronary Intervention; RCA = Right Coronary Artery; SD = Standard Deviation;

*Significant “within-group” trend towards EF$\geq$55%.

1 No statistical significance was found regarding the “within-group” allocation of LAD, LCX and RCA;

2 “Within-group” incidence of LAD significantly increased (P = 0.042).

doi:10.1371/journal.pone.0024964.t002

AF, CAD and Specific Antiarrhythmic Therapy
Regarding gender, in this study there was a higher incidence of men among the patients with CAD, but data did not reach statistical significance (72% vs 60%, p = 0.057, Table 1). Only in the comparison of patients with PCI versus patients without CAD or stable CAD, male gender was significantly more common in the PCI group (77% vs 60%, p = 0.028, Table 3). However, CAD is commonly associated with AF and maybe this association is somewhat stronger in males.

AF and need for revascularization
In addition to previous data, our study differentiates between patients with stable CAD (13%) and patients undergoing PCI (21%). Previously, AF had already been related to the severity of infarction [28,29] and described as an independent predictor of death in patients with left main CAD undergoing primary PCI [30]. The GISSI-3 study [4] analysed 17,944 patients after acute myocardial infarction and determined an incidence of in-hospital AF of 7.8%. Wilhelmsen et al. [6] diagnosed myocardial infarction in 34.2% of their male patient cohort before or after the diagnosis of AF. Chest pain during exertion was diagnosed in another 11.8% of men at baseline, comparable with the incidence of stable CAD (13%) in our study. Considering these incidences and the data presented in this study, especially before performing ablation therapy of AF in patients with palpitations and/or chest pain, CAD as underlying reason for these symptoms should be considered.

AF and location of stenosis
It is often speculated that atrial ischemia plays an important pathophysiological role in the genesis of AF. Hence significant stenosis in the proximal right coronary artery and the circumflex artery prior to the take-off of the atrial branches should increase the likelihood of AF in these patients. Previous studies report that
AF and treatment with a class Ic antiarrhythmic drug remains unclear and further investigations are needed. The precise group of patients in which CAD might be causal for AF of the RCA might contribute to less frequent episodes of AF. The basis of this data no answer can be given whether revascularization AF may present as a consequence of its symptoms [32], but on the undergoing PCI, CAD was more frequently detected in the RCA. Among LAD, LCX and RCA was found. Interestingly, in patients significant difference in the allocation of coronary artery stenosis localized before the take-off of atrial branches [31]. Comparing the data of the present study also have some implications for the selection of patients for treatment with flecainide and propafenone. The current AHA/ACC guidelines for the management of patients with AF recommend flecainide and propafenone for a single oral bolus dose (class IIa, “pill-in-the-pocket” concept), stating that these drugs should not be used in patients with CAD [20]. The incidence of “lone AF” in patients with persistent AF is 20–25% [33] and CAD should be taken into account as an underlying heart disease important for the consideration of ablation therapy [20] and the choice of the antiarrhythmic drug [20] Fig. 12). At least a stress test is reasonable in patients with signs or risk factors for CAD before administering an antiarrhythmic agent [20], considering that recurrent or chronic ischemia can also lead to impaired left ventricular conduction and thereby cause proarrhythmic effects of class IC antiarrhythmic drugs. Our data underline this recommendation and importantly provide data regarding the incidence of patients with AF undergoing PCI (21%) — a patient group which was identified as “high-thromboembolic-risk”, even having a CHADS2≤1 [34].

The results of the present study may give rise to further investigations, which are needed to elucidate the exact incidence and pathophysiological role of CAD in patients with AF.

Limitations

First, the non-randomized design of this single centre investigation might have potentially influenced the comparative analysis. Second, similar to previous studies, the results of this study are limited to hospitalized subjects. While caution is therefore needed in the interpretation of our data, we consider it improbable that these limitations have influenced our main findings.

Conclusions

In patients with AF presenting without previously diagnosed or excluded CAD, the overall incidence of CAD was relatively high at 34%. The incidence of patients undergoing PCI was 21% and the incidence of CAD in patients >70 years was even 41%. Increasing incidence of CRF in the western world should lead to a careful investigation respecting the FRS in patients presenting with AF to either definitely exclude or establish an early diagnosis of CAD. This could contribute to an early and safe therapeutic strategy considering the initiation of type Ic antiarrhythmics and oral anticoagulation.

Author Contributions

Conceived and designed the experiments: SK KS SL TS MB. Performed the experiments: SK KS SL. Analyzed the data: SK KS SL MB. Wrote the paper: SK MB. Statistical analysis: SK SL.

References

1. Go AS, Hylek EM, Philips KA, Chang Y, Henault LE, Selby JV, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) Study. JAMA 285: 2370–5.

2. Paquette M, Roy D, Talajic M, Newman D, Couturier A, et al. (2000) Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 86(7): 764–8.

3. Kannel WB, Abbott RD, Savage DD, McNamara PM (1982) Epidemologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306(17): 1018–22.

4. Pizzirotti F, Turaizza FM, Franzosi MG, Barlera S, Lleda A, et al. (2001) GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86(5): 527–32.

5. Gersh BJ, Tsang TSM, Barnes ME, Seward JB (2005) The changing epidemiology of non-valvular atrial fibrillation: The role of novel risk factors. Eur Heart J Supplements 7(Suppl C): C5–C11.

6. Wilhelmsen L, Rosengren A, Smedbol N, Saraste A, Björk AO, et al. (2002) Changes in risk for coronary heart disease among middle-aged men and women during a 15-year period: the prospective Stockholm Heart昕atal Study. Eur Heart J 23(12): 969–78.
Kannel WB, Abbott RD, Savage DD, McNamara PM (1983) Coronary heart disease and atrial fibrillation: The Framingham study. Am Heart J 106(2): 389–396.

Crijns HJ, Van Gelder IC, Van Gilst WH, Hilleghe H, Gosselink AM, et al. (1991) Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 68: 335–41.

AFFIRM Investigators (2002) Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. Am Heart J 143(6): 991–1001.

Lip GYH, Beavers DG (1995) History, epidemiology and importance of atrial fibrillation. BMJ 311(7016): 1361–3.

Haddad AH, Prchkov VK, Dean DC (1978) Chronic atrial fibrillation and coronary artery disease. Scandinavian cardiovascular journal 40: 152–159.

Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS (1988) Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 61: 714–717.

Hasdadi AH, Petklov VK, Dean DC (1976) Chronic atrial fibrillation and coronary artery disease. J Electrocardiol 11: 67–9.

Cheng TO (1974) Coronary artery disease as an uncommon cause of chronic atrial fibrillation. Clin Res 22: 268A.

Zipes DP (1984) Specific Arrhythmias: Diagnosis and Treatment. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia: W.B. Saunders. 700 p.

Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JGP, et al. (2008) Race II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362(15): 1439–1441.

Choi EK, Choi SI, Rivera JJ, Nasir K, Chang SA, et al. (2008) Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals. J Am Coll Cardiol 52(5): 537–63.

Camm AJ, Kirschof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 31(19): 2369–2429.

King SB, 3rd, Smith SC, Jr., Harshfield JW, Jr., Jacobs AK, Morrison DA, et al. (2000) Williams DO. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for the Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 117: 261–295.

Movahed MR, Hashemzadeh M, Jamal MM (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 105(3): 315–320.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22): 2864–70.

Van Waalwijk WC, Hart RG, Wells GA, Petersen P, Koudstaal PJ, et al. (2003) A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 163(8): 936–43.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 137: 263–272.

Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, et al. (1994) Kantaiharja PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74(3): 236–41.

Watson S, Arya A, Sulke N, Lip GY (2010) Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest 137(4): 869–876.

Behar S, Zahavi Z, Goldbourt U, Reicherc-Reiss H (1992) Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur Heart J 13(1): 45–50.

Goldberg RJ, Seeley D, Becker RC, Brady P, Chen ZY, et al. (1990) Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 119(5): 996–1001.

Min SY, Park DW, Yoon SC, Kim YH, Lee JY, et al. (2010) Major predictors of long-term clinical outcomes after coronary revascularization in patients with unprotected left main coronary disease: analysis from the MAIN-COMPARE study. Circ Cardiovasc Interv 3(2): 127–133.

Lokshyn S, Mewis C, Vahlkamp V (2000) Atrial fibrillation in coronary artery disease. Int J Cardiol 72(2): 133–40.

Dewar RJ, Lip GYH (2007) Identification, diagnosis and assessment of atrial fibrillation. Heart 93: 25–28.

Lévy S, Marecek M, Couble P, Guize L, Lekiefre J, et al. (1999) Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA study. The college of French Cardiologists. Circulation 99(23): 3028–35.

Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, Valencia-Martin J, Hurtado JA, et al. (2010) An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation undergoing percutaneous coronary revascularization. Chest Sep 23. [Epub ahead of print].